(UroToday.com) The Realizing Potential Combination and Personalized Therapy educational session at the European Society for Medical Oncology (ESMO) 2021 congress included a presentation by Dr. Toni Choueiri discussing whether there is an optimal first-line combination approach for metastatic renal cell carcinoma (RCC). The current first-line combination therapies that are FDA approved are listed as follows: